Presented by Mark Plavsic, Chief Technology Officer at Lysogene
Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C>) biologics. Adventitious agents (viruses, bacteria, mycoplasma, prions, etc) pose constant risk to these biologics, and, as such they may impact directly product and patient safety. It is therefore of supreme importance to intentionally (by design) employ effective measures across the whole C> product manufacturing process to mitigate risk of adventitious agents. This presentation will review various interconnected steps throughout the manufacturing process, from the raw materials to the fill and finish, that would, in concert, help mitigate the risk while providing a high degree of product safety by design.
FOLLOWED BY NEXT-GENERATION SEQUENCING FOR FAST AND PERFORMANT RESULTS APPLIED TO CELL AND GENE THERAPY PRODUCTS.
Presented by Dr. Magali Roche, Sales Manager, PathoQuest, Biologics Genomic Service